113
Participants
Start Date
July 31, 2009
Primary Completion Date
June 30, 2014
Study Completion Date
July 31, 2014
Everolimus
Everolimus 10mg PO daily continuously for all 28 days of a cycle
Bevacizumab
Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
Paclitaxel
Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
Placebo
Placebo PO daily continuously for all 28 days of a cycle
Bevacizumab
Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
Paclitaxel
Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Associates, Bethesda
Fairfax Northern Virginia Hem-Onc, Fairfax
Virginia Cancer Institute, Richmond
South Carolina Oncology Associates, PA, Columbia
Aventura Medical Center, Aventura
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center, Columbus
Oncology Hematology Care, Cincinnati
Texas Oncology, Dallas
Wilshire Oncology Medical Group, LaVerne
Eastern Connecticut Hematology Oncology, Norwich
Mercy Hospital, Portland
Collaborators (1)
Novartis
INDUSTRY
SCRI Development Innovations, LLC
OTHER